ANIP — ANI Pharmaceuticals, Inc.
Is ANIP overbought or oversold? Here is the current MarketMoodz read.
ANI Pharmaceuticals, Inc. (ANIP) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $69.99. The rating moved from Overbought to Neutral on November 16, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$69.99
- Last changeMoved from Overbought to Neutral on November 16, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
AI analysis
ANI Pharmaceuticals, Inc. (ANIP) benefits from a focused specialty/complex-generic manufacturing footprint and recurring contract revenue that position it to capture demand from distributors and larger pharma consolidators seeking outsourced capabilities. In the near term, measured market tone and defensive flows into healthcare support stability, while potential contract wins or utilization improvements could drive upside. Key vulnerabilities include regulatory/quality events, customer concentration, pricing pressure in generics, and supply-chain cost dynamics. Absent company-specific negative catalysts, the outlook is for modest appreciation as execution on manufacturing efficiency and new commercial wins materialize; conversely, any inspection or major customer loss would create downside risk.
Key factors
- Niche specialty and complex-generic manufacturing capabilities that command higher margins than commodity generics
- Established customer relationships and contract-manufacturing/service revenue streams providing recurring demand
- Sector thematic tailwinds: distributor shift to specialty care and large‑cap pharma consolidation increasing demand for outsourced manufacturing and specialty supply chains
- Defensive interest in pharma exposure in the current market tone, supporting relative stability in the near term
- Potential for selective new product launches or contract wins to drive upside to revenue and utilization
- Relatively limited short-term macro/policy shocks in the market window, reducing volatility risk ahead of earnings/updates
Risks
- Regulatory and quality risk (FDA inspections, remediation costs, recalls) that can materially disrupt production and revenue
- Customer concentration risk — loss or volume reduction from a large buyer would weigh heavily on near-term results
- Intense pricing competition in generics and potential margin compression as larger players and entrants compete
- Reimbursement and payer pressure (including Medicare/Medicaid program integrity actions) that could reduce demand or net pricing
- Supply-chain disruptions or raw-material cost inflation that squeeze margins and production timelines
- Small-cap liquidity and volatility risk, including potential adverse reaction to any disappointing quarterly guidance or headlines
See today's live rating, score and targets
Members see the live hourly rating for ANIP — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.